Literature DB >> 15466991

Justified and unjustified use of growth hormone.

A J van der Lely1.   

Abstract

Growth hormone (GH) replacement therapy for children and adults with proven GH deficiency due to a pituitary disorder has become an accepted therapy with proven efficacy. GH is increasingly suggested, however, as a potential treatment for frailty, osteoporosis, morbid obesity, cardiac failure, and various catabolic conditions. However, the available placebo controlled studies have not reported many significant beneficial effects, and it might even be dangerous to use excessive GH dosages in conditions in which the body has just decided to decrease GH actions. GH can indeed induce changes in body composition that are considered to be advantageous to GH deficient and non-GH deficient subjects. In contrast to GH replacement therapy in GH deficient subjects, however, excessive GH action due to GH misuse seems to be ineffective in improving muscle power. Moreover, there are no available study data to indicate that the use of GH for non-GH deficient subjects should be advocated, especially as animal data suggest that lower GH levels are positively correlated with longevity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466991      PMCID: PMC1743118          DOI: 10.1136/pgmj.2003.017467

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  59 in total

1.  Can human aging be postponed?

Authors:  M R Rose
Journal:  Sci Am       Date:  1999-12       Impact factor: 2.142

2.  Assessment of growth parameters and life span of GHR/BP gene-disrupted mice.

Authors:  K T Coschigano; D Clemmons; L L Bellush; J J Kopchick
Journal:  Endocrinology       Date:  2000-07       Impact factor: 4.736

3.  Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study.

Authors:  J P Frindik; J Baptista
Journal:  Pediatrics       Date:  1999-10       Impact factor: 7.124

4.  Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women.

Authors:  K H Lange; F Isaksson; A Juul; M H Rasmussen; J Bülow; M Kjaer
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-11       Impact factor: 4.310

Review 5.  Successful aging. How increased life expectancy and medical advances are changing geriatric care.

Authors:  C K Cassel
Journal:  Geriatrics       Date:  2001-01

6.  Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement.

Authors:  G Johannsson; B A Bengtsson; J Ahlmén
Journal:  Am J Kidney Dis       Date:  1999-04       Impact factor: 8.860

Review 7.  Growth hormone and ageing.

Authors:  G Johannsson; J Svensson; B A Bengtsson
Journal:  Growth Horm IGF Res       Date:  2000-04       Impact factor: 2.372

Review 8.  Endocrinological aspects of aging in men: is hormone replacement of benefit?

Authors:  H Janssens; D M Vanderschueren
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2000-09       Impact factor: 2.435

Review 9.  The impact of recombinant human growth hormone treatment on final adult height.

Authors:  R N Fine; E K Sullivan; A Tejani
Journal:  Pediatr Nephrol       Date:  2000-07       Impact factor: 3.714

10.  Use of human GH in elderly patients with accidental hip fracture.

Authors:  A J Van der Lely; S W Lamberts; K W Jauch; B A Swierstra; H Hertlein; D Danielle De Vries; M A Birkett; P C Bates; W F Blum; A F Attanasio
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

View more
  3 in total

1.  Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion.

Authors:  Susana Sangiao-Alvarellos; María J Vázquez; Luis Varela; Rubén Nogueiras; Asish K Saha; Fernando Cordido; Miguel López; Carlos Diéguez
Journal:  Endocrinology       Date:  2009-07-16       Impact factor: 4.736

2.  Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications.

Authors:  Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  Int J Pept       Date:  2010-02-09

3.  Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.

Authors:  Caroline Sievers; Dorothee M Baur; Anja Schwanke; Michael Buchfelder; Michael Droste; Klaus Mann; Günter K Stalla
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.